Danaher's third quarter 2026 earnings beat estimates as core revenue growth excluding respiratory reached 5.5%

Danaher reported third quarter 2026 results that exceeded analyst expectations on both the top and bottom lines, driven by an acceleration in bioprocessing demand and disciplined execution. Non-GAAP adjusted diluted EPS grew 11.5% year-over-year to $2.11, supported by $6.6 billion in revenue. Following the strong performance, management raised the full-year 2026 adjusted EPS guidance midpoint to $8.595.

Key Highlights

• Adjusted diluted net earnings per share of $2.11 beat the $1.92 consensus estimate, representing an 11.5% increase over the prior year.
• Core revenue growth excluding respiratory testing reached 5.5%, surpassing the 5% estimate and signaling an inflection point in biopharma inventory destocking.
• The Biotechnology segment delivered 5.0% core revenue growth, successfully capturing delayed shipments from the previous quarter.
• Operating cash flow remained robust at $1.9 billion, with non-GAAP free cash flow reaching $1.6 billion for the quarter.